Researcher.Life Logo

Molecular Pharmaceutics : Impact Factor & More

eISSN: 1543-8392pISSN: 1543-8384

Aims and Scope of Molecular Pharmaceutics

Molecular Pharmaceutics is a peer-reviewed scientific journal covering research on the molecular mechanistic understanding of drug delivery and drug delivery systems, including physical and pharmaceutical chemistry, biochemistry and biophysics, molecular and cellular biology, and polymer and materials science. First published in 2004 by the American Chemical Society, it is considered one of the most prestigious journals in the field of pharmaceutics, physical pharmacy and drug delivery. Its publication frequency switched from bimonthly to monthly in 2012. According to the Journal Citation Reports, the journal has a 2019 impact factor of 4.321. The current editor-in-chief is Lynne S. Taylor, who is preceded founding editor-in-chief Gordon L. Amidon. Less

Key Metrics

CiteScore
9.2
Eigenfactor
0.01 - 0.05
H-Index
149
Impact Factor
< 5
Scite Index
0.93 5-Year SI
SJR
Q1Drug Discovery
SNIP
1.09
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Molecular Pharmaceutics

Molecular Pharmaceutics Journal Specifications

Overview
Publisher AMER CHEMICAL SOC
Language English
Frequency Bi-monthly
General Details
LanguageEnglish
FrequencyBi-monthly
Publication Start Year2004
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in Molecular Pharmaceutics ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Molecular Pharmaceutics

Insect-Cell-Produced AAV2 Vectors Activate Myeloid Innate Immune Response Featuring NETosis.
  • 19 May 2026
  • Molecular pharmaceutics
An 18F-labeled ECL1i-Based C-C Chemokine Receptor Type 2 Radiotracer for Cardiac Inflammation Imaging.
  • 18 May 2026
  • Molecular pharmaceutics
Establishment of 68Ga-DOTA-Based Pretargeted Radioimmunodiagnosis.
  • 18 May 2026
  • Molecular pharmaceutics
Construction of a 89Zr-Labeled Specific Antibody Fragment for the Noninvasive Detection of Mesothelin-Overexpressing Tumors.
  • 12 May 2026
  • Molecular pharmaceutics
Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design.
  • 12 May 2026
  • Molecular pharmaceutics
Correction to "Detection of Voltage-Gated Potassium Channels 1.3 via Immuno-PET Visualizes Rheumatoid Arthritis".
  • 11 May 2026
  • Molecular pharmaceutics
Insect-Cell-Produced AAV2 Vectors Activate Myeloid Innate Immune Response Featuring NETosis.
  • 19 May 2026
  • Molecular pharmaceutics
An 18F-labeled ECL1i-Based C-C Chemokine Receptor Type 2 Radiotracer for Cardiac Inflammation Imaging.
  • 18 May 2026
  • Molecular pharmaceutics
Establishment of 68Ga-DOTA-Based Pretargeted Radioimmunodiagnosis.
  • 18 May 2026
  • Molecular pharmaceutics
Construction of a 89Zr-Labeled Specific Antibody Fragment for the Noninvasive Detection of Mesothelin-Overexpressing Tumors.
  • 12 May 2026
  • Molecular pharmaceutics
Controlling the Size and Shape of Monoclonal Antibody Particles through Crystallization Process Design.
  • 12 May 2026
  • Molecular pharmaceutics
Correction to "Detection of Voltage-Gated Potassium Channels 1.3 via Immuno-PET Visualizes Rheumatoid Arthritis".
  • 11 May 2026
  • Molecular pharmaceutics

FAQs on Molecular Pharmaceutics